242 related articles for article (PubMed ID: 9456263)
21. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
[TBL] [Abstract][Full Text] [Related]
22. An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group.
AIDS; 1999 Apr; 13(5):565-73. PubMed ID: 10203381
[TBL] [Abstract][Full Text] [Related]
23. Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
Simonelli C; Zanussi S; Sandri S; Comar M; Lucenti A; Talamini R; Bortolin MT; Giacca M; De Paoli P; Tirelli U
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):20-7. PubMed ID: 9928725
[TBL] [Abstract][Full Text] [Related]
24. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
[TBL] [Abstract][Full Text] [Related]
25. [Therapy of HIV infection: combination drug therapy effective, immunotherapy still experimental].
Dtsch Med Wochenschr; 1997 Apr; 122(15):A32. PubMed ID: 9147936
[No Abstract] [Full Text] [Related]
26. [Monitoring anti-retroviral treatment].
Miró JM; Pumarola T; Soriano V; Bouza E
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():44-50. PubMed ID: 9053027
[No Abstract] [Full Text] [Related]
27. Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection.
Anderson AM; Kosinski AS; Bartlett JA
Antivir Ther; 2007; 12(7):1041-8. PubMed ID: 18018762
[TBL] [Abstract][Full Text] [Related]
28. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
29. Virologic and immunologic response to nucleoside reverse-transcriptase inhibitor therapy among human immunodeficiency virus-infected infants and children.
Palumbo PE; Raskino C; Fiscus S; Pahwa S; Schutzbank T; Spector SA; Baker CJ; Englund JA
J Infect Dis; 1999 Mar; 179(3):576-83. PubMed ID: 9952363
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
[TBL] [Abstract][Full Text] [Related]
31. [Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
López-Martínez C; Guarner J; Magis-Rodríguez C; Uribe-Zúñiga P; del Río-Chiriboga C
Rev Invest Clin; 1998; 50(4):335-9. PubMed ID: 9830323
[TBL] [Abstract][Full Text] [Related]
32. No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
Simonelli C; Comar M; Zanussi S; De Paoli P; Tirelli U; Giacca M
AIDS; 1997 Aug; 11(10):1299-300. PubMed ID: 9256953
[No Abstract] [Full Text] [Related]
33. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
34. Immune modulation with IL-2 and IL-12.
Boonprakong L
STEP Perspect; 1997; 9(1):9-12. PubMed ID: 11364273
[TBL] [Abstract][Full Text] [Related]
35. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.
Levy Y; Capitant C; Houhou S; Carriere I; Viard JP; Goujard C; Gastaut JA; Oksenhendler E; Boumsell L; Gomard E; Rabian C; Weiss L; Guillet JG; Delfraissy JF; Aboulker JP; Seligmann M
Lancet; 1999 Jun; 353(9168):1923-9. PubMed ID: 10371571
[TBL] [Abstract][Full Text] [Related]
36. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
Lafeuillade A; Poggi C; Tamalet C; Profizi N; Tourres C; Costes O
J Infect Dis; 1997 May; 175(5):1051-5. PubMed ID: 9129065
[TBL] [Abstract][Full Text] [Related]
37. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group.
Gerstoft J; Melander H; Bruun JN; Pedersen C; Głtzsche PC; Berglund O; Mathiesen L; Skinhłj P; Norrby SR
Scand J Infect Dis; 1997; 29(2):121-8. PubMed ID: 9181646
[TBL] [Abstract][Full Text] [Related]
38. [Initial anti-retroviral treatment (therapeutic approach to patients without previous treatment)].
Gatell JM; Guerra L; Pérez-Elías MJ; Santamaría JM
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():20-3. PubMed ID: 9053022
[No Abstract] [Full Text] [Related]
39. Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline.
Iuliano R; Forastieri G; Brizzi M; Mecocci L; Mazzotta F; Ceccherini-Nelli L
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Apr; 14(5):408-14. PubMed ID: 9170414
[TBL] [Abstract][Full Text] [Related]
40. [Pancreatic disease in patients with HIV treated with didanosine (DDI)].
Ortega González E; Martín Herrera A; López de Medrano V; de Lelis FP; Ronda Gasulla FA; Gil Egea M; Ballester Belda E; Herrera Ballester A
Rev Esp Enferm Dig; 1996 Feb; 88(2):114-7. PubMed ID: 8664067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
